Diabetic Neuropathy: A Guide to Pain Management
- PMID: 38967712
- DOI: 10.1007/s11916-024-01293-9
Diabetic Neuropathy: A Guide to Pain Management
Abstract
Purpose of review: Diabetic neuropathy is a common complication of diabetes mellitus (DM) and can affect up to 50% of DM patients during their lifetime. Patients typically present with numbness, tingling, pain, and loss of sensation in the extremities. Since there is no treatment targeting the underlying mechanism of neuropathy, strategies focus on preventative care and pain management.
Recent findings: Up to 69% of patients with diabetic neuropathy receive pharmacological treatment for neuropathic pain. The United States Food and Drug Administration (FDA) confirmed four drugs for painful diabetic neuropathy (PDN): pregabalin, duloxetine, tapentadol, and the 8% capsaicin patch. Nonpharmacological treatments such as spinal cord stimulation (SCS) and transcutaneous electrical nerve stimulation (TENS) both show promise in reducing pain in DM patients. Despite the high burden associated with PDN, effective management remains challenging. This update covers the background and management of diabetic neuropathy, including its epidemiology, pathogenesis, preventative care, and current therapeutic strategies.
Keywords: Capsaicin; Duloxetine; Painful Diabetic Neuropathy; Pregabalin; Spinal Cord Stimulation; Tapentadol.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
References
-
- Taylor RS, Lad SP, White JL, Stauss TG, Healey BE, Sacks NC, et al. Health care resource utilization and costs in patients with painful diabetic neuropathy treated with 10 kHz spinal cord stimulation therapy. J Manag Care Spec Pharm. 2023;29:1021–9. Utilization of SCS resulted in lower rates of hospitalization and consequently lower health care costs. - PubMed - PMC
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
